ID   HAOX1_HUMAN             Reviewed;         370 AA.
AC   Q9UJM8; Q14CQ0; Q9UPZ0; Q9Y3I7;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   12-APR-2017, entry version 150.
DE   RecName: Full=Hydroxyacid oxidase 1;
DE            Short=HAOX1;
DE            EC=1.1.3.15;
DE   AltName: Full=Glycolate oxidase;
DE            Short=GOX;
GN   Name=HAO1; Synonyms=GOX1, HAOX1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=10978532; DOI=10.1016/S0167-4781(00)00161-5;
RA   Williams E.L., Cregeen D.P., Rumsby G.;
RT   "Identification and expression of a cDNA for human glycolate
RT   oxidase.";
RL   Biochim. Biophys. Acta 1493:246-248(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10777549; DOI=10.1074/jbc.275.17.12590;
RA   Jones J.M., Morrell J.C., Gould S.J.;
RT   "Identification and characterization of HAOX1, HAOX2, and HAOX3, three
RT   human peroxisomal 2-hydroxy acid oxidases.";
RL   J. Biol. Chem. 275:12590-12597(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Stavrides G.S., Huckle E.J., Deloukas P.;
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Watanabe T.;
RT   "Isolation and characterization of a novel human liver-specific gene
RT   homologous to the plant glycolate oxidase by the differential display
RT   method.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) IN COMPLEX WITH FMN; GLYOXYLATE
RP   AND 4-CARBOXY-5-DODECYLSULFANYL-1,2,3-TRIAZOLE, FUNCTION, COFACTOR,
RP   CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=18215067; DOI=10.1021/bi701710r;
RA   Murray M.S., Holmes R.P., Lowther W.T.;
RT   "Active site and loop 4 movements within human glycolate oxidase:
RT   implications for substrate specificity and drug design.";
RL   Biochemistry 47:2439-2449(2008).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.84 ANGSTROMS) IN COMPLEX WITH FMN AND THE
RP   SYNTHETIC INHIBITOR CCPST.
RX   PubMed=20054120; DOI=10.1107/S1744309109041670;
RA   Bourhis J.M., Vignaud C., Pietrancosta N., Gueritte F., Guenard D.,
RA   Lederer F., Lindqvist Y.;
RT   "Structure of human glycolate oxidase in complex with the inhibitor 4-
RT   carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazole.";
RL   Acta Crystallogr. F 65:1246-1253(2009).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) IN COMPLEX WITH FMN.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human hydroxyacid oxidase 1.";
RL   Submitted (FEB-2009) to the PDB data bank.
CC   -!- FUNCTION: Has 2-hydroxyacid oxidase activity. Most active on the
CC       2-carbon substrate glycolate, but is also active on 2-hydroxy
CC       fatty acids, with high activity towards 2-hydroxy palmitate and 2-
CC       hydroxy octanoate. {ECO:0000269|PubMed:18215067}.
CC   -!- CATALYTIC ACTIVITY: (S)-2-hydroxy acid + O(2) = 2-oxo acid +
CC       H(2)O(2). {ECO:0000269|PubMed:18215067}.
CC   -!- COFACTOR:
CC       Name=FMN; Xref=ChEBI:CHEBI:58210;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00683,
CC         ECO:0000269|PubMed:18215067};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=141 uM for glycolate {ECO:0000269|PubMed:18215067};
CC         KM=40 uM for 2-hydroxy octanoate {ECO:0000269|PubMed:18215067};
CC         KM=2200 uM for glyoxylate {ECO:0000269|PubMed:18215067};
CC   -!- PATHWAY: Organic acid metabolism; glycolate degradation; 3-
CC       phospho-D-glycerate from glycolate: step 1/4.
CC   -!- SUBCELLULAR LOCATION: Peroxisome.
CC   -!- TISSUE SPECIFICITY: Liver.
CC   -!- SIMILARITY: Belongs to the FMN-dependent alpha-hydroxy acid
CC       dehydrogenase family. {ECO:0000255|PROSITE-ProRule:PRU00683}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF244134; AAF63219.1; -; mRNA.
DR   EMBL; AF231916; AAF40199.1; -; mRNA.
DR   EMBL; AL121739; CAB57329.1; -; mRNA.
DR   EMBL; AB024079; BAA82872.1; -; mRNA.
DR   EMBL; AL021879; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113665; AAI13666.1; -; mRNA.
DR   EMBL; BC113667; AAI13668.1; -; mRNA.
DR   CCDS; CCDS13100.1; -.
DR   RefSeq; NP_060015.1; NM_017545.2.
DR   UniGene; Hs.193640; -.
DR   PDB; 2NZL; X-ray; 1.35 A; A=1-370.
DR   PDB; 2RDT; X-ray; 1.95 A; A=1-370.
DR   PDB; 2RDU; X-ray; 1.65 A; A=1-370.
DR   PDB; 2RDW; X-ray; 1.95 A; A=1-370.
DR   PDB; 2W0U; X-ray; 2.84 A; A/B/C/D=1-370.
DR   PDBsum; 2NZL; -.
DR   PDBsum; 2RDT; -.
DR   PDBsum; 2RDU; -.
DR   PDBsum; 2RDW; -.
DR   PDBsum; 2W0U; -.
DR   ProteinModelPortal; Q9UJM8; -.
DR   SMR; Q9UJM8; -.
DR   BioGrid; 119941; 4.
DR   IntAct; Q9UJM8; 1.
DR   STRING; 9606.ENSP00000368066; -.
DR   BindingDB; Q9UJM8; -.
DR   ChEMBL; CHEMBL4229; -.
DR   DrugBank; DB07907; (2S)-2-HYDROXYOCTANOIC ACID.
DR   DrugBank; DB07060; 3-(INDOL-3-YL) LACTATE.
DR   DrugBank; DB03884; 3-Phenylpyruvic Acid.
DR   DrugBank; DB02279; Benzoylformic Acid.
DR   DrugBank; DB02164; N-Sulfo-Flavin Mononucleotide.
DR   DrugBank; DB03247; Riboflavin Monophosphate.
DR   iPTMnet; Q9UJM8; -.
DR   PhosphoSitePlus; Q9UJM8; -.
DR   BioMuta; HAO1; -.
DR   DMDM; 13124294; -.
DR   PaxDb; Q9UJM8; -.
DR   PeptideAtlas; Q9UJM8; -.
DR   PRIDE; Q9UJM8; -.
DR   DNASU; 54363; -.
DR   Ensembl; ENST00000378789; ENSP00000368066; ENSG00000101323.
DR   GeneID; 54363; -.
DR   KEGG; hsa:54363; -.
DR   UCSC; uc002wmw.2; human.
DR   CTD; 54363; -.
DR   DisGeNET; 54363; -.
DR   GeneCards; HAO1; -.
DR   HGNC; HGNC:4809; HAO1.
DR   HPA; HPA049552; -.
DR   MIM; 605023; gene.
DR   neXtProt; NX_Q9UJM8; -.
DR   OpenTargets; ENSG00000101323; -.
DR   PharmGKB; PA29185; -.
DR   eggNOG; KOG0538; Eukaryota.
DR   eggNOG; COG1304; LUCA.
DR   GeneTree; ENSGT00390000018717; -.
DR   HOGENOM; HOG000217463; -.
DR   HOVERGEN; HBG051881; -.
DR   InParanoid; Q9UJM8; -.
DR   KO; K11517; -.
DR   OMA; QKSVYDY; -.
DR   OrthoDB; EOG091G0ADA; -.
DR   PhylomeDB; Q9UJM8; -.
DR   TreeFam; TF313363; -.
DR   BRENDA; 1.1.3.15; 2681.
DR   Reactome; R-HSA-389661; Glyoxylate metabolism and glycine degradation.
DR   SABIO-RK; Q9UJM8; -.
DR   UniPathway; UPA00864; UER00830.
DR   EvolutionaryTrace; Q9UJM8; -.
DR   GenomeRNAi; 54363; -.
DR   PRO; PR:Q9UJM8; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101323; -.
DR   CleanEx; HS_HAO1; -.
DR   ExpressionAtlas; Q9UJM8; baseline and differential.
DR   Genevisible; Q9UJM8; HS.
DR   GO; GO:0005782; C:peroxisomal matrix; TAS:Reactome.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0003973; F:(S)-2-hydroxy-acid oxidase activity; IDA:UniProtKB.
DR   GO; GO:0010181; F:FMN binding; IDA:UniProtKB.
DR   GO; GO:0008891; F:glycolate oxidase activity; IDA:UniProtKB.
DR   GO; GO:0047969; F:glyoxylate oxidase activity; TAS:Reactome.
DR   GO; GO:0052853; F:long-chain-(S)-2-hydroxy-long-chain-acid oxidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052854; F:medium-chain-(S)-2-hydroxy-acid oxidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0052852; F:very-long-chain-(S)-2-hydroxy-acid oxidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0001561; P:fatty acid alpha-oxidation; IDA:UniProtKB.
DR   GO; GO:0046296; P:glycolate catabolic process; IDA:UniProtKB.
DR   GO; GO:0046487; P:glyoxylate metabolic process; TAS:Reactome.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR012133; Alpha-hydoxy_acid_DH_FMN.
DR   InterPro; IPR000262; FMN-dep_DH.
DR   InterPro; IPR008259; FMN_hydac_DH_AS.
DR   Pfam; PF01070; FMN_dh; 1.
DR   PIRSF; PIRSF000138; Al-hdrx_acd_dh; 1.
DR   PROSITE; PS00557; FMN_HYDROXY_ACID_DH_1; 1.
DR   PROSITE; PS51349; FMN_HYDROXY_ACID_DH_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Flavoprotein; FMN; Oxidoreductase;
KW   Peroxisome; Phosphoprotein; Reference proteome.
FT   CHAIN         1    370       Hydroxyacid oxidase 1.
FT                                /FTId=PRO_0000206318.
FT   DOMAIN        1    365       FMN hydroxy acid dehydrogenase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00683}.
FT   NP_BIND     291    315       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683}.
FT   NP_BIND     291    295       FMN binding. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   MOTIF       368    370       Microbody targeting signal.
FT                                {ECO:0000255}.
FT   ACT_SITE    260    260       Proton acceptor.
FT   BINDING      26     26       Substrate.
FT   BINDING     108    108       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   BINDING     130    130       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   BINDING     132    132       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   BINDING     132    132       Substrate.
FT   BINDING     158    158       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   BINDING     167    167       Substrate.
FT   BINDING     236    236       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   BINDING     258    258       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   BINDING     263    263       Substrate.
FT   BINDING     315    315       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00683,
FT                                ECO:0000269|PubMed:18215067,
FT                                ECO:0000269|PubMed:20054120,
FT                                ECO:0000269|Ref.10}.
FT   MOD_RES     184    184       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9WU19}.
FT   MOD_RES     194    194       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WU19}.
FT   MOD_RES     230    230       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   HELIX         8     18       {ECO:0000244|PDB:2NZL}.
FT   HELIX        21     28       {ECO:0000244|PDB:2NZL}.
FT   HELIX        35     46       {ECO:0000244|PDB:2NZL}.
FT   STRAND       47     49       {ECO:0000244|PDB:2NZL}.
FT   STRAND       64     66       {ECO:0000244|PDB:2NZL}.
FT   STRAND       69     77       {ECO:0000244|PDB:2NZL}.
FT   HELIX        83     85       {ECO:0000244|PDB:2NZL}.
FT   HELIX        90    101       {ECO:0000244|PDB:2NZL}.
FT   STRAND      104    107       {ECO:0000244|PDB:2NZL}.
FT   HELIX       115    121       {ECO:0000244|PDB:2NZL}.
FT   STRAND      125    131       {ECO:0000244|PDB:2NZL}.
FT   STRAND      134    136       {ECO:0000244|PDB:2NZL}.
FT   HELIX       137    149       {ECO:0000244|PDB:2NZL}.
FT   STRAND      155    158       {ECO:0000244|PDB:2NZL}.
FT   HELIX       168    173       {ECO:0000244|PDB:2NZL}.
FT   TURN        189    193       {ECO:0000244|PDB:2RDU}.
FT   HELIX       205    212       {ECO:0000244|PDB:2NZL}.
FT   HELIX       219    225       {ECO:0000244|PDB:2NZL}.
FT   STRAND      233    238       {ECO:0000244|PDB:2NZL}.
FT   HELIX       241    249       {ECO:0000244|PDB:2NZL}.
FT   STRAND      254    257       {ECO:0000244|PDB:2NZL}.
FT   HELIX       260    262       {ECO:0000244|PDB:2NZL}.
FT   HELIX       271    282       {ECO:0000244|PDB:2NZL}.
FT   STRAND      285    290       {ECO:0000244|PDB:2NZL}.
FT   HELIX       297    305       {ECO:0000244|PDB:2NZL}.
FT   STRAND      309    313       {ECO:0000244|PDB:2NZL}.
FT   HELIX       315    346       {ECO:0000244|PDB:2NZL}.
FT   HELIX       352    354       {ECO:0000244|PDB:2NZL}.
FT   HELIX       357    359       {ECO:0000244|PDB:2NZL}.
FT   STRAND      360    362       {ECO:0000244|PDB:2RDT}.
SQ   SEQUENCE   370 AA;  40924 MW;  C683C6F7CB5FD323 CRC64;
     MLPRLICIND YEQHAKSVLP KSIYDYYRSG ANDEETLADN IAAFSRWKLY PRMLRNVAET
     DLSTSVLGQR VSMPICVGAT AMQRMAHVDG ELATVRACQS LGTGMMLSSW ATSSIEEVAE
     AGPEALRWLQ LYIYKDREVT KKLVRQAEKM GYKAIFVTVD TPYLGNRLDD VRNRFKLPPQ
     LRMKNFETST LSFSPEENFG DDSGLAAYVA KAIDPSISWE DIKWLRRLTS LPIVAKGILR
     GDDAREAVKH GLNGILVSNH GARQLDGVPA TIDVLPEIVE AVEGKVEVFL DGGVRKGTDV
     LKALALGAKA VFVGRPIVWG LAFQGEKGVQ DVLEILKEEF RLAMALSGCQ NVKVIDKTLV
     RKNPLAVSKI
//
